Spironolacton in der Behandlung der portalen Hypertonie bei Leberzirrhose: Ein neues Wirkungsprinzip?
- 1 January 1985
- journal article
- abstracts
- Published by Georg Thieme Verlag KG in Deutsche Medizinische Wochenschrift (1946)
- Vol. 110 (46) , 1774-1776
- https://doi.org/10.1055/s-2008-1069085
Abstract
Five patients with liver cirrhosis, portal hypertension and oesophageal varices received spironolactone in daily doses of 50-200 mg. Measurements of hepatic vein occlusion pressure at intervals of 1 to 5 months showed a pressure reduction of between 9 and 11 mm Hg. Thus the pressure lowering effect of spironolactone is about the same as that of beta-blockers. Since spironolactone is without the well known side effects of beta-blockers this therapeutic approach has wide application in the long term drug therapy of portal hypertension.Keywords
This publication has 0 references indexed in Scilit: